TGTX Q4 2023 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+54863.8% YoY

Gross Profit

$36M81.9% margin

Operating Income

-$12M-28.4% margin

Net Income

-$14M-32.8% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-73.5%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$330M

Total Liabilities

$169M

Stockholders' Equity

$161M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$80,000	+54863.8%
Gross Profit	$36M	$77,000	+46685.7%
Operating Income	-$12M	-$52M	+76.0%
Net Income	-$14M	-$53M	+72.8%

Revenue Segments

Product

$67M100%